The non-staff members of the IAS–USA Board of Directors participate in a volunteer capacity. They are not compensated for their role in governing/overseeing the IAS–USA.

In accordance with IAS–USA policy on disclosure and conflicts of interest, information regarding conflicts of interest is obtained from all parties with control over activity content (ie, directors, officers, activity chairs, faculty, authors, and IAS–USA staff), and conflicts of interest of those parties are resolved.

Below are the financial interests that the volunteer members of the Board of Directors have had with commercial companies within the last 12 months of the date of disclosure (noted next to each):

Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on advisory boards for GlaxoSmithKline, Merck & Co, Inc, and Pfizer Inc, and chaired data and safety monitoring boards for Johnson & Johnson Research, Ltd (Australia) and Achillion Pharmaceuticals, Inc. (Updated 02/12/09)

Dr Currier has received research grants and research support from Merck & Co, Inc, Schering Plough Corp, Theratechnologies Inc, and Tibotec Therapeutics. She has served as a scientific advisor to Bristol-Myers Squibb, Merck & Co, Inc, and Tibotec Therapeutics and on a data and safety monitoring boards for Achillion Pharmaceuticals, Inc, and Koronis Pharmaceuticals. (Updated 02/05/09)

Dr del Rio has received research grants awarded to Emory University from GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, and Sanofi Pasteur. He served as a consultant or received honoraria from Bristol-Myers Squibb, Merck & Co, Inc, and Trinity Biotech Plc. (Updated 02/12/09)

Dr Gallant has received grants and research support from Gilead Sciences, Inc, Merck & Co, Inc, Pfizer Inc, Roche Laboratories, and Tibotec Therapeutics. He has received honoraria from Abbott Laboratories, Gilead Sciences, Inc, GlaxoSmithKline, and Monogram Biosciences, Inc. He has served as a consultant to or was on the advisory boards for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, RAPID Pharmaceuticals, Inc, Schering-Plough Corp, and Tibotec Therapeutics. He is a member of data and safety monitoring boards for Abbott Laboratories, Gilead Sciences, Inc, Koronis Pharmaceuticals, and VIRxSYS Corp. (Updated 02/05/09)

Dr Gulick has served as a consultant to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pathway Pharmaceuticals Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Schering-Plough Corp, Tibotec Therapeutics, and Virostatics. He also serves as Chair of a data and safety monitoring board for Koronis Pharmaceuticals. (Updated 03/25/09)

Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 02/05/09)

Dr Richman has served as a consultant to Anadys Pharmaceuticals, Inc, Biota, Bristol-Myers Squibb, Chimerix, Inc, Gen-Probe, Gilead Sciences, Inc, Idenex Pharmaceuticals, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, and Roche Laboratories. (Updated 04/15/09)

Dr Saag has received grants and research support from Achillion Pharmaceuticals, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Merck & Co, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, and Tibotec Therapeutics. He has served as a consultant to Ardea Biosciences, Inc, Avexa, Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Monogram Biosciences, Inc, Pain Therapeutics, Inc, Panacos Pharmaceuticals, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Roche Laboratories, Tibotec Therapeutics, Tobira Therapeutics, and Virco Lab, Inc. (Updated 02/05/09)

Dr Schooley served as a consultant to Achillion Pharmaceuticals, Inc, Anadys Pharmaceuticals, Inc, Ardea Biosciences, Inc, Chimerix, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, iTherX, Inc, Koronis Pharmaceuticals, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, TaiMed Biologics, Tibotec Therapeutics, and Vertex Pharmaceuticals. He had stock options for Achillion Pharmaceuticals, Inc, and Monogram Biosciences, Inc. (Updated 02/13/09)

Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tobira Therapeutics and has been on an endpoint adjudication committee for Schering-Plough Corp for an ongoing clinical trial. He is a member of data safety and monitoring boards for Merck & Co, Inc, and TaiMed Biologics. He served as a consultant to Pfizer Inc and received an unrestricted educational grant from GlaxoSmithKline-Italy. (Updated 02/05/09)